| EGFR-TKI在非小细胞肺癌二线治疗与一线治疗中的疗效比较 |
| |
| 引用本文： | 陈良安. EGFR-TKI在非小细胞肺癌二线治疗与一线治疗中的疗效比较[J]. 解放军医学杂志, 2011, 36(8): 783-787 |
| |
| 作者姓名： | 陈良安 |
| |
| 作者单位： | 解放军总医院呼吸内科,北京,100853 |
| |
| 摘 要： | 含铂两药联合化疗方案目前仍是晚期非小细胞肺癌(NSCLC)的标准一线治疗方案,分子靶向药物为晚期NSCLC患者提供了新的治疗选择.临床研究证实,在晚期NSCLC患者的二线治疗中,表皮生长因子酪氨酸激酶抑制剂(EGFR-TKI)与标准化疗相比具有明确的非劣效性.然而,肿瘤组织标本检测显示EGFR基因突变阳性的NSCLC患...
|
| 关 键 词： | 表皮生长因子酪氨酸激酶抑制剂 癌,非小细胞肺 一线治疗 二线治疗 |
Comparison of therapeutic effects between EGFR-TKI in first-line and second-line therapy in non-small cell lung cancer (NSCLC) patients |
| |
| CHEN Liang-an. Comparison of therapeutic effects between EGFR-TKI in first-line and second-line therapy in non-small cell lung cancer (NSCLC) patients[J]. Medical Journal of Chinese People's Liberation Army, 2011, 36(8): 783-787 |
| |
| Authors: | CHEN Liang-an |
| |
| Affiliation: | CHEN Liang-an.Department of Respiratory Diseases,General Hospital of PLA,Beijing 100853,China |
| |
| Abstract: | Platinum-based chemotherapy is still the standard first-line treatment for patients with advanced non-small cell lung cancer(NSCLC).Molecular targeted agents provide a new option for NSCLC patients.Clinical trial had shown that survival rate with epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI) treatment was not inferior compared with platinum-based chemotherapy in second line NSCLC therapy.However,for the patients with EGFR gene mutation,a better outcome has been achieved with the use o... |
| |
| Keywords: | epidermal growth factor receptor tyrosine kinase inhibitor carcinoma non-small-cell lung first-line therapy second-line therapy |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
